NT 2
Alternative Names: NT-2Latest Information Update: 26 Sep 2025
At a glance
- Originator Neurotez
- Class Antidementias; Peptides
- Mechanism of Action Cytoplasmic linker protein 170-presenilin 1 interaction inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease
Most Recent Events
- 10 Sep 2025 Early research in Alzheimer's disease (Prevention) in USA (unspecified route) prior to September 2025 (Neurotez pipeline, September 2025)